Blood Tests Show Promise for Early Cancer Detection but Face Major Hurdles

A simple blood draw that screens for more than 50 types of cancer. It sounds like science fiction — and for decades, it was. But a new class of diagnostics called multi-cancer early detection (MCED) tests has moved from the laboratory bench to the brink of FDA approval, raising enormous hopes and equally enormous questions about whether these tests can deliver on their transformative promise.

The field's frontrunner, GRAIL's Galleri test, has generated headline after headline: seven-fold increases in cancer detection, a new federal law guaranteeing Medicare coverage, and the largest-ever randomized trial of a blood-based cancer screen. But beneath the optimism lies a more complicated story — one of missed clinical endpoints, a 50% stock crash, unresolved questions about false positives and overdiagnosis, and a price tag that could strain health systems already buckling under the weight of cancer care.

How It Works: Reading Cancer's Methylation Fingerprint

Unlike traditional tumor marker blood tests, MCED tests don't hunt for a single protein or genetic mutation. Galleri analyzes methylation patterns in cell-free DNA (cfDNA) — fragments of genetic material shed by tumors into the bloodstream [1]. By examining which genes are chemically switched on or off across these fragments, the test can both detect a cancer signal and predict where in the body the cancer originated, a capability known as cancer signal origin (CSO) prediction.

In real-world data from more than 111,000 individuals published in Nature Communications in 2025, the Galleri test correctly predicted the cancer signal origin in 87% of cases with a confirmed cancer diagnosis [2]. That accuracy matters enormously: it determines whether a patient undergoes targeted imaging of the right organ or embarks on a costly, anxiety-inducing diagnostic odyssey.

The test reports 99.5% specificity — meaning roughly 1 in 200 healthy people will receive a false positive signal [3]. That sounds reassuringly precise, but at population scale the arithmetic shifts dramatically. Screen one million 50-year-olds and roughly 5,000 will receive a cancer signal without actually having cancer, triggering follow-up imaging, biopsies, and psychological distress.

The PATHFINDER 2 Triumph

GRAIL's case for FDA approval rests heavily on PATHFINDER 2, a registrational study of 35,878 adults aged 50 and older across the United States and Canada. Results presented at the European Society for Medical Oncology (ESMO) Congress in October 2025 were striking [4]:

• Adding Galleri to standard recommended screenings (breast, cervical, colorectal, and lung) produced a more than seven-fold increase in overall cancer detection rate.
• More than half of the cancers detected by Galleri were found in early stages (I and II), when treatment is most effective.
• The positive predictive value — the probability that a positive test result truly indicates cancer — reached 61.6%, a significant improvement over the 43-50% range seen in earlier trials [5].
• No serious adverse events were reported from the diagnostic workup triggered by test results.

These numbers represent a genuine leap. For the majority of cancers — pancreatic, ovarian, liver, stomach, and dozens of others — no routine screening test exists at all. Patients are typically diagnosed only after symptoms appear, often at late stages when five-year survival rates plummet.

Source: GDELT Project

Data as of Mar 11, 2026CSV

The NHS-Galleri Setback

But the most consequential data point arrived on February 19, 2026, and it was not the result GRAIL had hoped for.

The NHS-Galleri trial — the largest randomized controlled trial of any MCED test, enrolling more than 142,000 participants aged 50 to 77 across England — missed its primary endpoint [6]. The study was designed to demonstrate a statistically significant reduction in Stage III and IV cancer diagnoses among those receiving Galleri versus standard care. It did not achieve that threshold.

The market reaction was immediate and brutal. GRAIL's shares plunged roughly 50% in a single day, erasing billions in market capitalization [7]. Analysts described it as a "major setback" for the company and the MCED field broadly.

Yet buried within the wreckage were secondary findings that experts called "clinically meaningful" [8]. When researchers narrowed the analysis to 12 of the deadliest cancer types — including pancreatic, lung, and ovarian cancers — Galleri plus standard screening produced a substantial reduction in Stage IV diagnoses, with the effect strengthening over successive annual screening rounds, reaching greater than 20% reduction by the second and third rounds. Emergency cancer presentations, which carry significantly higher mortality and healthcare costs, also declined meaningfully in the screening arm.

GRAIL announced plans to extend the trial's follow-up period by 6 to 12 months, arguing that the cancer stage-shift effect may need more time to materialize across all cancer types [6]. Independent oncologists offered cautious agreement: cancers with long latency periods may require several rounds of annual screening before population-level stage migration becomes statistically apparent.

The FDA and Medicare Equation

Despite the NHS-Galleri trial's mixed results, the regulatory path for Galleri continues to advance. GRAIL completed submission of its Premarket Approval (PMA) application to the FDA on January 29, 2026, under the agency's Breakthrough Device Designation — a pathway created to expedite review of transformative diagnostics [9]. The submission includes data from PATHFINDER 2's 25,490 consented U.S.-based participants with one year of follow-up.

On the legislative front, Congress acted before the FDA. The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was signed into law on February 3, 2026, as part of a bipartisan spending package that passed the House 341 to 88 [10]. The law creates a new Medicare benefit category for FDA-approved MCED tests, with coverage expected to begin in 2028. Critically, the legislation specifies that these tests will complement, not replace, existing cancer screenings — an important guardrail given concerns about test limitations.

The law gives the Centers for Medicare and Medicaid Services (CMS) authority to determine coverage parameters through an evidence-based process, meaning approval by the FDA alone won't guarantee blanket reimbursement [10]. CMS will evaluate clinical benefit, appropriate patient populations, and screening intervals before setting coverage rules.

The False Positive and Overdiagnosis Dilemma

The most persistent criticism of MCED testing centers on two intertwined risks: false positives and overdiagnosis.

A false positive — a cancer signal in a person who doesn't have cancer — carries tangible harms. Patients face invasive follow-up procedures, radiation exposure from imaging, surgical biopsies, and significant psychological burden. Research published in PMC has documented that even comorbid conditions such as autoimmune diseases, liver disease, and chronic inflammation can produce aberrant DNA methylation patterns that mimic cancer signals, complicating result interpretation [3].

Overdiagnosis poses a subtler but potentially larger problem. Some cancers detected at early stages — particularly certain thyroid, prostate, and breast cancers — are so slow-growing that they would never cause symptoms or death within a patient's lifetime. Detecting them through an MCED screen can trigger aggressive treatment (surgery, chemotherapy, radiation) that produces real harm for zero benefit. The thyroid cancer epidemic in South Korea, where widespread screening led to a 15-fold increase in diagnoses with no reduction in mortality, stands as a cautionary precedent [3].

As of early 2026, MCED testing is not recommended in any major clinical guidelines and is not considered a replacement for standard screening practices [11]. The American Cancer Society, the United States Preventive Services Task Force (USPSTF), and the National Comprehensive Cancer Network (NCCN) have all declined to issue formal screening recommendations pending more definitive mortality data.

The Cost Question

Galleri currently retails at approximately $949 per test and is not covered by insurance [12]. For a test designed to be repeated annually, the out-of-pocket burden is substantial — and the cost-effectiveness math is far from settled.

Modeling studies of blood-based cancer screening have raised red flags. A 2024 analysis published in Gastroenterology found that even with the assumption of higher screening participation, triennial blood-based colorectal cancer screening at the CMS-specified minimum sensitivity (74%) and specificity (90%) was not projected to be cost-effective compared with established screening strategies like colonoscopy [13].

Source: World Bank

Data as of Feb 24, 2026CSV

The cost context matters. The United States already spends more than $13,400 per capita on healthcare annually — more than double what the United Kingdom, France, or Japan spend — yet does not achieve correspondingly better cancer outcomes [14]. Adding a new annual screening test for tens of millions of adults over 50 could add billions in direct testing costs alone, before accounting for the downstream costs of follow-up diagnostics, overdiagnosis, and overtreatment.

Proponents counter that the economics look different when MCED tests catch cancers that currently have no screening pathway. Treating Stage IV pancreatic cancer costs far more — financially, physically, and emotionally — than treating it at Stage I or II. A 2025 analysis by the ASCO Post estimated that shifting even a fraction of late-stage diagnoses to early-stage detection could produce net savings across the healthcare system [12].

The Competitive Landscape

GRAIL is not alone. Exact Sciences, the company behind the Cologuard colorectal cancer test, is developing its own MCED platform and was among the companies applauding the Medicare coverage legislation [10]. Guardant Health, Freenome, and several academic consortia are pursuing alternative liquid biopsy approaches using different biomarkers — circulating tumor cells, exosomes, microRNAs, and proteomics panels.

The race is consequential. The first MCED test to achieve both FDA approval and favorable CMS coverage terms will have an enormous first-mover advantage in a market that analysts project could eventually reach $50 billion or more annually [5]. That prize explains why the field continues to attract massive investment despite the NHS-Galleri setback.

What Comes Next

The next 12 to 18 months will be decisive. The FDA's review of GRAIL's PMA application will determine whether Galleri becomes the first FDA-approved MCED test — a milestone that would unlock the Medicare coverage pathway created by the Sewell Act. GRAIL's extended follow-up data from the NHS-Galleri trial, expected in the second half of 2026, could either rehabilitate or further undermine the case for population-wide screening [6].

Meanwhile, the scientific community is grappling with a fundamental question that no single trial can answer: does detecting cancer earlier through a blood test actually save lives? The distinction between finding more cancers and reducing cancer deaths is not semantic — it is the difference between a medical revolution and an expensive false start.

The 34% decline in U.S. cancer mortality since 1991 — averting an estimated 4.5 million deaths — was driven by smoking reduction, improved treatment, and early detection through established screenings like mammography and colonoscopy [15]. MCED testing could potentially accelerate that trajectory. But the history of cancer screening is also littered with interventions that found more disease without reducing suffering — and sometimes increased it.

For now, the blood test that could change everything remains exactly that: a could. The science is genuine. The promise is real. The proof, however, is still being drawn.